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Objective: The John Cunningham virus (JCV) is a generally benign and asymptomatic polyomavirus.
Due to an association of the anti-integrin agent natalizumab with progressive multifocal leukoencephal-
opathy (PML) in patients with multiple sclerosis (MS), a newly developed anti-JCV antibody assay has
been implemented as a risk-stratiﬁcation tool for natalizumab-treated patients with MS. This viewpoint
offers insight and perspective regarding the potential unapproved use of the anti-JCV antibody assay in
rheumatoid arthritis (RA) and examines how rheumatologists can best assist patients.
Methods: A primary literature search was conducted to identify articles on the number of cases of PML
associated with natalizumab in patients with MS, the number of cases of PML associated with patients
with rheumatic disease, PML incidence in the general population, serum-based assays to detect JCV
exposure, and clinical PML presentation and treatment methods.
Results: Risk of PML in patients with RA receiving biologics appears orders of magnitude lower than that
expected in natalizumab-treated patients with MS (1 in 1000). If patients with RA are risk stratiﬁed
assuming an anti-JCV antibody seropositivity of 60%, theoretically 23,400 anti-JCV antibody-positive
patients would have to receive rituximab before potentially observing 1 PML case.
Conclusions: Data currently indicate that rheumatologists should not order the anti-JCV antibody assay
for patients requiring biologics. Monitoring relevant symptoms indicative of emerging PML might
provide greater value to patients, thus prompting interventional measures that could affect prognosis.
& 2015 The Authors. Published by Elsevier HS Journals, Inc. This is an open access article under the CC BY-
NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).Introduction
The John Cunningham virus (JCV) is a generally benign and
asymptomatic polyomavirus. Similar to other viruses, such as
Epstein–Barr virus (EBV) and cytomegalovirus (CMV), its preva-
lence is high in the general population [1,2]. Most exposures occur
in childhood; however, rates of infection increase with age: 10% of
children aged 1–5 years are positive for the JCV antibody com-
pared with 40–60% aged 10 years, 50% aged 20–29 years, and 68%
aged 60–100 years [3–5]. Consequences of either EBV or CMV
infections are generally benign but can lead to severer HS Journals, Inc. This is an open
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mer).complications. For example, EBV infection can lead to lymphoma
development after immunosuppressant exposure and CMV infec-
tion to CMV-related retinitis in patients with human immunode-
ﬁciency virus (HIV) [6,7]. Similarly, JCV causes no clinical illness at
the time of infection but can, in rare circumstances, lead to
progressive multifocal leukoencephalopathy (PML)—a demyelinat-
ing disease of the central nervous system (CNS) that is often lethal
or can result in permanent neurological sequelae [8]. This view-
point offers insight and perspective regarding the potential unap-
proved use of the anti-JCV antibody assay in rheumatoid arthritis
(RA) and examines how rheumatologists can best assist patients.Literature search methodology
A primary literature search was conducted to identify articles
on the number of cases of PML associated with natalizumab in
patients with MS, the number of cases of PML associated with
patients with rheumatic disease, PML incidence in the general
population, serum-based assays to detect JCV exposure, and
clinical PML presentation and treatment methods.access article under the CC BY-NC-ND license
Table 1
Estimated incidence of PML in the United States stratiﬁed by risk factor [16]
Anti-JCV Ab
negative
Natalizumab
exposure (months)
Anti-JCV Ab positive
No prior
immunosuppressant
use
Prior
immunosuppressant
use
1/1000 1–24 o1/1000 1/1000
24–48 3/1000 13/1000
49–72 7/1000 9/1000
Ab, antibody; JCV, John Cunningham virus; PML, progressive multifocal
leukoencephalopathy.
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Several critical steps must occur to induce PML, explaining the
disconnect between the high JCV infection rate in the general
population and the extremely low-observed PML incidence. For a
productive infection to occur, JCV must undergo gene rearrange-
ment(s), be re-expressed from latent or persistent sites, and lastly,
because of failed CNS immunosurveillance, enter the brain and
infect glial tissues [8]. Importantly, PML development depends on
alterations in a patient's immune response, as exempliﬁed by
reports of PML in patients with suppressed immune systems due
to HIV infection or cancer. Interestingly, whereas PML was initially
reported in 5% of patients with HIV, introduction of effective
antiretroviral therapies led to subsequent improvement of a
patient's immune system and signiﬁcant reductions in PML cases
[9,10].
Despite the frequency of immunosuppressive treatment for
multiple sclerosis (MS) or inﬂammatory bowel disorders, PML
was not reported until 2005, when 3 cases (2 with MS and 1 with
Crohn disease) associated with natalizumab, a new anti-integrin
agent, were presented; these events led to its market withdrawal
[8]. Because of the otherwise beneﬁcial effects in MS, natalizumab
was reintroduced after risk-mitigation strategies and a controlled
distribution program were devised.
As of September 2, 2014, 495 PML cases were reported in
patients with MS exposed to natalizumab [11]. With the caveat
that reporting in controlled programs is likely greater than with
voluntary submission, this number contrasts with the few cases
reported for other immunosuppressant drugs/autoimmune dis-
eases. A total of 34 conﬁrmed cases were identiﬁed in patients
with rheumatic diseases exposed to synthetic and biologic disease-
modifying antirheumatic drugs [12].
Although very rare in RA, PML can be devastating, thus
justifying efforts to mitigate individual patient risk. Given the
successful implementation of a risk-mitigation strategy in
natalizumab-treated patients with MS using a newly developed
anti-JCV antibody assay, we wondered whether a similar approach
could be applied to other diseases for which PML has been
reported in association with immunosuppressant[13,14]. Speciﬁ-
cally, could the anti-JCV antibody assay assist in estimating PML
risk in conditions such as RA?Serum-based assay to detect JCV exposure
The JCV Stratify assay, developed to detect JCV-speciﬁc anti-
bodies in the serum of patients with MS, is an enzyme-linked
immunosorbent assay (ELISA). Of patients with MS treated with
natalizumab, 54% were positive for anti-JCV antibodies, with a
false-negative rate of 2.5% [15]. Retrospective analyses of large
patient cohorts indicated that patients with MS—who were JCV
seropositive, had prior immunosuppressant exposure, and were
treated with natalizumab for Z24 months—were at signiﬁcantly
greater risk of developing PML (Table 1) [13,15,16]. Whereas this
algorithm does not indicate or mandate that individuals with an
estimated higher risk should not receive natalizumab, it helps
physicians estimate the beneﬁt/risk and discuss treatment options
with patients. Although a negative test could be interpreted as no
PML risk, it is worth noting that, as stated above, the anti-JCV test
can give false-negative results [15,17]. Patients with negative JCV
antibody test results excreted the virus in urine in 37% of cases or
were shown to have positive T-cell responses to the virus,
indicating prior exposure [17,18]. Consideration should also be
given to the potential need to repeat negative tests, given the 2%
annual seroconversion rate [15].Physicians contemplating using the JCV antibody assay in
patients with RA should note that the assay has not been validated
or proven to have clinical utility in this population, in striking
contrast with its demonstrated clinical utility as a risk-stratifying
tool in patients with MS exposed to natalizumab [19]. In anti-JCV
antibody-positive patients with MS and no prior immunosuppres-
sant use, serum/plasma antibody levels, measured as index, may
differentiate PML risk [19]. No data on JCV antibody assay use in RA
have been reported. Whereas in patients with MS, overall JCV
seropositivity is estimated at 50–60% and higher (66.5%) in
patients aged Z60 years (consistent with the general population),
seropositivity is possibly greater in patients with RA, who tend to
be older [5,14,20]. Assay validation in non-MS patient cohorts is
lacking. ELISA-based, the JCV antibody assay is susceptible to
interferences, in particular from rheumatoid factor, present in up
to 70% of patients with RA and a major source of interference in
immunoassays [21]. In fact, the JCV antibody assay package insert
speciﬁes that samples containing antinuclear antibodies or rheu-
matoid factor have not been evaluated and may cause erroneous
results [22].Considerations on PML risk-mitigation across diseases
PML incidence rate in patients with RA is 3-fold higher than
in the general population (1.0 vs 0.3/100,000 person-years) [23].
PML is frequently associated with biologic use although it has, very
rarely, been reported in biologic-naive patients [23]. The US Food
and Drug Administration (FDA) Adverse Event Reporting System
database had 10 conﬁrmed PML cases in patients with RA reported
through March 31, 2010: 6 received rituximab, 1 inﬂiximab, and
3 nonbiologic immunosuppressive agents [12]. Risk of PML in
patients with RA receiving biologics appears orders of magnitude
lower than that expected in natalizumab-treated patients with MS
(1 in 1000, incidence increases with increasing exposure time;
Table 1) [16,23]. A recently proposed classiﬁcation of therapies
associated with PML assigned natalizumab and rituximab to
distinct classes [8]. Class 1 agents including natalizumab unequiv-
ocally introduce substantially increased PML risk regardless of
preexisting conditions, whereas class 2 agents such as rituximab
appear to increase PML risk at signiﬁcantly lower levels than class
1 agents, and most patients have either underlying conditions or
receive other medications recognized to increase PML risk.
Risk mitigation in natalizumab-treated patients with MS iden-
tiﬁes higher-risk patients on the basis of JCV antibody assay
positivity, duration of treatment, and prior use of other immuno-
suppressants [13]. Efforts have yet to identify clear unifying factors
in rheumatic diseases [12,24,25]. In systemic lupus erythematosus
(SLE), PML risk is 10-fold greater than in RA, indicating that the
underlying condition is itself a risk [25]. Cases of rituximab-
associated PML have often been characterized by poten-
tially confounding factors such as underlying diagnoses (SLE,
Table 2
Reporting rate of conﬁrmed PML in patients with RA treated with rituximaba
Anti-JCV Ab positive Anti-JCV Ab negative Overall
PML, n 8 0 8
No PML, n 187,189 124,798 311,987
Total, n 187,197 124,798 311,995
Reporting rate per 100,000 unique patients (95% CI) 4.3 (1.9–8.4) 0 (0–3.0) 2.6 (1.1–5.1)
Patients requiring treatment to identify 1 PML case, n 23,400 – –
Ab, antibody; JCV, John Cunningham virus; PML, progressive multifocal leukoencephalopathy; RA, rheumatoid arthritis.
a Numbers were calculated using Genentech data and based on the assumption that, in rituximab-treated patients with RA, the prevalence of anti-JCV seropositivity is
60%. However, in RA, the prevalence of anti-JCV seropositivity in rituximab-treated patients has neither been tested nor conﬁrmed. The estimated worldwide cumulative
exposure to rituximab from marketing experience has been taken from the 2015 periodic beneﬁt–risk evaluation report (1062808).
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immunosuppressant use [8,26]. Although prior exposure to JCV is
likely the least common denominator in the emergence of PML in
either natalizumab-treated patients with MS or biologic-treated
patients with rheumatic diseases, the algorithm developed for
natalizumab-treated patients with MS should not be readily
extrapolated to other diseases. The (fortunate) lack of enough
cases in rheumatic diseases impedes analyses required to identify
potential predisposing conditions speciﬁc to RA. Commenting on
an anti-integrin similar to natalizumab, the FDA recently cautioned
against extrapolating ﬁndings across different treatments, popu-
lations, and environments [27].
Because of the low PML incidence reported in patients with RA,
the potential positive predictive value of the anti-JCV assay would
be too low to serve as a valuable risk-mitigation option. If patients
with RA are risk stratiﬁed assuming an anti-JCV antibody seropo-
sitivity of 60%, theoretically 23,400 anti-JCV antibody-positive
patients would have to receive rituximab before potentially
observing 1 PML case (Table 2). The test would not be informative
in predicting risk, and positive results could produce unnecessary
anxiety, warranting additional patient counseling.Table 3
Clinical trials subjective checklist of relevant neurological signs and symptoms for PML
Symptoms “Compared to how you usually
feel, have you had a signiﬁcant
change in any of the following?”
Yes No
1. Have you been experiencing any
persistent difﬁculty with your vision such
as loss of vision or double vision? Have
you been having trouble with reading?
2. Have you been experiencing any
persistent difﬁculty speaking or having
your speech understood by others?
3. Have you been experiencing any
persistent weakness in an arm or a leg?
4. Have you noticed yourself regularly
bumping into things or having difﬁculty
writing?
5. Have you regularly been experiencing
difﬁculty understanding others?
6. Have you had persistent problems with
your memory or thinking?
7. Have you been experiencing any
persistent numbness or other loss of
sensation?
PML, progressive multifocal leukoencephalopathy.Practical PML clinical considerations
Although a PML-predicting test is desirable, the current
assay provides only a means to demonstrate virus exposure.
Data currently indicate that rheumatologists should not order
the anti-JCV antibody assay for patients requiring biologics.
Monitoring relevant symptoms indicative of emerging PML
might provide greater value to patients, thus prompting inter-
ventional measures that could affect prognosis. PML manifests
clinically through neurological symptoms, such as impaired
vision, motor weakness, and changes in mentation [28].
Although neurological examinations are uncommon when
assessing patients with RA, some simple assessments are not
an insurmountable task for rheumatologists. Neurology experts
have devised a simple questionnaire assessing recent changes
in vision, speech, gait, sensation, comprehension, coordination,
and personality to monitor patients in clinical trials evaluating
therapeutics with PML risk (Table 3) [29]. Routine monitoring
is important because early diagnosis and treatment withdrawal
are the most signiﬁcant prognostic factors affecting outcome
[30].safety assessment[29]
If the answer is “yes,”
obtain a description of the
symptom(s) with examples
Applicable objective test(s): document
results on PML objective checklist
Test visual ﬁelds and ocular motility.
Casual observation of speech output for
dysarthria or aphasia. Ask patient to
name a few objects and repeat a
multipart phrase.
Test for pronator drift (Barre maneuver)
and/or ﬁxation on arm roll. Assess the
ability to hop on either foot; foot and
ﬁnger tapping. Test muscle strength.
Ask for spontaneous writing sample and
observe ﬁnger to nose, heel to shin, and
tandem gait.
Ability to follow serial commands.
Recall of 3 objects over 1 minute with
distraction; ability to follow commands.
Test sensation side to side with pinprick.
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Impaired cognitive functions in patients with RA receiving
biologics may be more than a manifestation of aging. Lacking
predictive tests, physicians should be alert for the very rare case of
PML and be prepared to rapidly query a few neurological signs and
symptoms, enabling prompt implementation of measures that can
drastically improve prognosis and outcome, such as immediate
suppression of the offending agent [8,30].Acknowledgments
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